Bettale G, De Carlis L, Alberti A, Dughetti L, Rizzi P, Rondinara G, Belli L, Del Favero E, Belli L, Idéo G
Centro di Epatologia, Ospedale Niguarda Cà Granda, Milano, Italy.
Ital J Gastroenterol. 1992 Jan;24(1):1-7.
From December 1985 to December 1990, 100 liver orthotopic transplantations (OLTX) were performed in 89 adults with cirrhosis and various other liver diseases; eight patients had two transplants and three of these had three transplants. Organ perfusion was done with Eurocollins in the first 30, then with UW solution. Immunosuppressants were a combination of cyclosporin A and steroids for the first 30 patients, and then a combination of antilymphocyte globulin, azathioprine, methylprednisolone and cyclosporin A. The OLTXs were examined as a whole and also divided into two groups, one for 1985-88 and one for 1989-90. The cumulative survival was 63% after 12 months, 40% after 36 and 42 months. It was poor for the patients who received transplants between 1985 and 1988, but for the second group, survival was improved to 78% after 12 and 18 months. For neoplastic patients, overall survival was 49% after 18 months and 23% after 36 and 42 months. In the second group it was markedly better (83% after 18 months). The recurrence rate for patients surviving more than three months was 17% for hepatocellular carcinoma and 50% for cholangiocarcinoma. Five patients (38%) out of 13 HBsAg-positives before the transplant and surviving more than three months had recurrent hepatitis-B virus. The remaining eight patients are HBsAg negative at present. The improved actuarial survival for the second group is accounted for by the better surgical and intensive care given now and the methodological differences.
1985年12月至1990年12月期间,对89例患有肝硬化及其他各种肝脏疾病的成人进行了100例原位肝移植(OLTX);8例患者接受了两次移植,其中3例接受了三次移植。最初30例器官灌注采用欧洲柯林斯液,之后采用UW液。前30例患者的免疫抑制剂为环孢素A和类固醇联合使用,之后为抗淋巴细胞球蛋白、硫唑嘌呤、甲泼尼龙和环孢素A联合使用。对所有原位肝移植进行了整体检查,并分为两组,一组为1985 - 1988年,另一组为1989 - 90年。12个月后的累积生存率为63%,36个月和42个月后为40%。1985年至1988年接受移植的患者生存率较差,但第二组在12个月和18个月后生存率提高到了78%。对于肿瘤患者,18个月后的总生存率为49%,36个月和42个月后为23%。在第二组中明显更好(18个月后为83%)。存活超过三个月的患者中,肝细胞癌的复发率为17%,胆管癌为50%。移植前HBsAg阳性且存活超过三个月的13例患者中有5例(38%)出现乙肝病毒复发。其余8例患者目前HBsAg阴性。第二组精算生存率的提高归因于现在更好的手术和重症监护以及方法学上的差异。